Therapy for recurrent ovarian cancer

Area of Science:

• Gynecologic Oncology
• Medical Oncology
• Clinical Cancer Research

Background:

• Advanced ovarian cancer primary treatment combines surgery and platinum/taxane chemotherapy.
• Most ovarian cancer patients experience relapse, necessitating effective recurrent disease management.
• Treatment-free interval is crucial for guiding relapse therapy decisions.

Purpose of the Study:

• To outline treatment strategies for recurrent ovarian cancer based on relapse timing.
• To differentiate between platinum-refractory and platinum-sensitive recurrent ovarian cancer.
• To emphasize quality of life considerations for platinum-refractory patients.

Main Methods:

• Retrospective analysis of treatment outcomes for recurrent ovarian cancer.
• Classification of patients based on platinum sensitivity (relapse within or after 6 months).
• Evaluation of treatment modalities including chemotherapy and secondary tumor debulking.

Main Results:

• Patients relapsing within 6 months of primary treatment are platinum-refractory with poor prognosis.
• Platinum-refractory patients require palliative care focused on quality of life.
• Patients relapsing after >6 months are platinum-sensitive, potentially achieving durable remissions with platinum-based chemotherapy, sometimes with secondary debulking.

Conclusions:

• Recurrent ovarian cancer management is stratified by the treatment-free interval.
• Platinum-based chemotherapy remains a cornerstone for platinum-sensitive recurrent ovarian cancer.
• Individualized treatment decisions, prioritizing quality of life, are essential for platinum-refractory ovarian cancer.